Literature DB >> 33870113

The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey.

Neslihan Duzkale1, Olcay Kandemir2.   

Abstract

OBJECTIVE: BRCA1/2 genes play a role in the etiopathogenesis of 10%-30% of triple-negative breast cancer (TNBC). This study aims to investigate the BRCA1/2 genes and the demographic and clinicopathological features in patients with TNBC. The study also examined the impact of cancer history of TNBC individuals' relatives on the risk of BRCA1/2 mutation carriership rate.
MATERIALS AND METHODS: The BRCA1/2 genes of 65 women diagnosed with TNBC between 2011 and 2017 were investigated using next-generation sequencing. We analyzed the correlations of patients' demographic and clinicopathologic parameters and family history with BRCA1/2 mutation status. We used the χ2-test, t-test, Mann-Whitney U test, and logistic regression statistical methods.
RESULTS: The BRCA1/2 mutation carrier rate was 16.9%. Patients who had BRCA1/2 mutations were compared with those who did not in terms of demographic and clinicopathological parameters. In the BRCA1/2 mutation carrier group, the Ki-67 index and the number of relatives with cancer were higher than the BRCA1/2 non-carrier group. Logistic regression analysis revealed that when the number of relatives with breast or ovarian cancer was ≥2, the risk of carrying the BRCA1/2 mutation increased by 15-fold. Regardless of the type of cancer (including cancers in other organs besides breast or ovary), the risk of carrying the BRCA1/2 mutation increased 1.3 times with each increase in the number of relatives with cancer for the patient with TNBC.
CONCLUSION: In cases with a diagnosis of TNBC, a significant relationship exists between the number of relatives with cancer in the family history and the risk of carrying mutations in the BRCA1/2 genes. This relationship can be confirmed further by large-scale studies with more cases. ©Copyright 2021 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  BRCA1/2; family history; hereditary cancer; triple-negative breast cancer

Year:  2021        PMID: 33870113      PMCID: PMC8025727          DOI: 10.4274/ejbh.galenos.2020.5909

Source DB:  PubMed          Journal:  Eur J Breast Health


  19 in total

1.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2005-06-29

2.  Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.

Authors:  Axel Muendlein; Bettina H Rohde; Klaus Gasser; Anton Haid; Stephanie Rauch; Elena Kinz; Heinz Drexel; Wera Hofmann; Verena Schindler; Rita Kapoor; Thomas Decker; Alois H Lang
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-15       Impact factor: 4.553

3.  Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets.

Authors:  Neslihan Duzkale; Nilnur Eyerci; Berna Oksuzoglu; Taner Teker; Olcay Kandemir
Journal:  Eur J Med Genet       Date:  2019-09-26       Impact factor: 2.708

4.  Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.

Authors:  J Lorenzo Bermejo; K Hemminki
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

5.  Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.

Authors:  Jacqueline Mersch; Michelle A Jackson; Minjeong Park; Denise Nebgen; Susan K Peterson; Claire Singletary; Banu K Arun; Jennifer K Litton
Journal:  Cancer       Date:  2014-09-15       Impact factor: 6.860

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Evaluation of treatment outcomes of triple-negative breast cancer.

Authors:  Ahmet Cinkaya; Mustafa Akin; Adem Sengul
Journal:  J Cancer Res Ther       Date:  2016 Jan-Mar       Impact factor: 1.805

8.  Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.

Authors:  M Digennaro; D Sambiasi; S Tommasi; B Pilato; S Diotaiuti; A Kardhashi; G Trojano; A Tufaro; A V Paradiso
Journal:  Hered Cancer Clin Pract       Date:  2017-05-25       Impact factor: 2.857

9.  P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.

Authors:  Yunbao Pan; Yufen Yuan; Guoshi Liu; Yongchang Wei
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

10.  The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.

Authors:  Yong Tao Li; Duo Ni; Liang Yang; Qian Zhao; Jiang Hua Ou
Journal:  Eur J Med Res       Date:  2014-06-25       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.